A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations
Clinical trial NCT06132932 · COMPLETED
Trial details
- NCT number
- NCT06132932
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-03
- Primary completion
- 2023-01-03
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.